Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study (DRACULA 1)

The Role of the Glutamatergic Neurotransmission in Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study

Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior.

Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

Patients will be recruited by the physician in charge of the study or collaborators of the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution. In the study, exposure to citalopram treatment will be 12 weeks with follow-up every 4 weeks. At each participant, at the time of enrollment, will be assigned a unique code so that only the local investigators can trace the subject's identity. As part of a scheduled visit to assess the clinical diagnosis, the PPD patient will be offered to participate in the study, after the appropriate signing of informed consent, the verification of absence of criteria for exclusion and existence of the study inclusion criteria. If these criteria are met, some demographic and clinical medical history of the women with PPD will be collected, as already provided by clinical practice for the management of the disease. Patients will undergo MRI scanning at baseline at the S.C. Neuroradiology of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and will begin the pharmacological treatment with citalopram. It is emphasized that the administration of citalopram therapy for the treatment of depressive symptomatology will be proposed and carried out in the patient due to clinical needs, based on the judgment of the competent physician and as would already be the case in practice, thus completely independent of participation or non-participation in the present study. Neuroimaging data will be obtained with a Philips 3T magnetic resonance imaging MRI machine. For each patient enrolled in the study, a structural T1 sequence (3D MPRAGE) is acquired.

T1-weighted MRI images will be used to study the differences brain morphology, including the volumes of gray matter (GM) and white matter (WM) and voxel-based morphometry. In a comparison parallel between regions of interest (ROIs), regional volumes will be estimated using the automated anatomical labeling atlas (AAL) as a reference, with emphasis on the dorsolateral PFC (DL)/ventrolateral (VL), cingulate cortex, amygdala and hippocampus. Further regional analysis will allow estimation, in addition to cortical volumes and subcortical volumes, cortical thickness, cortical surface area, and the cortical gyrification of the Desikan-Killiany atlas regions. During treatment with citalopram, patients will be visited, as per standard clinical practice, every 4 weeks. At each of these follow-up visits will be administered to patients by medical specialists the Brief Psychiatric Rating Scale (BPRS) and the Hamilton Depression Rating Scale (HAM- D) to study symptomatology depression. Patients will be, instead, self-administered in Italian language the Maternal Postnatal Attachment Scale (MPAS) and the Parental Stress Index (PSI) to investigate mother-child attachment and parental stress. The time scheduled for completion of both scales will be about 40 minutes. At 12 weeks, as per practice, the MRI scan will be repeated at the S.C. Neuroradiology Department of the Foundation. The following variables will be collected as part of this study: socio-demographic variables (age, schooling, socio-economic);

  • clinical/anamnestic variables (age of onset, duration of untreated treated, drug therapy, comorbidities, familiarity, substance abuse/dependence);
  • BPRS and HAM-D scales scores for symptomatology assessment (T0, T1, T2, T3);
  • MPAS and PSI scales scores for the assessment of mothers child attachment. (T0, T1, T2, T3);
  • MRI scan data (T0, T3): the images will be used to study brain morphological differences, including GM and WM volumes, and voxel-based morphometry. In a parallel comparison between regions of interest (ROI), regional volumes will be estimated using as a reference the automated anatomical labeling atlas (AAL), with particular attention to the dorsolateral (DL)/ventrolateral (VL) PFC, cingulate cortex, amygdala and hippocampus. A further regional analysis will make it possible to estimate, in addition to cortical and subcortical volumes, the thickness cortical, cortical surface area and cortical gyrification of the Desikan-Killiany atlas regions.

Studietype

Observasjonsmessig

Registrering (Antatt)

15

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Michigan
      • Milan, Michigan, Italia, 20100
        • Rekruttering
        • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 40 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Women, aged 18 years to 40 years of age or older, with PPD who will be enrolled by the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution.

Beskrivelse

Inclusion Criteria:

  • Age between 18 and 40 years;
  • female gender;
  • PPD diagnosed by DSM-5 structured clinical interview support (SCID-5) by trained medical personnel;
  • comorbidity with metabolic syndrome, which can lead to brain damage and cognitive flaws;
  • need to start citalopram therapy for clinical needs (and therefore independent of study participation) or already on therapy for no more than two weeks;
  • moderate to severe depression according to the 17-item HAM-D (score 14-24);
  • absence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • Absence of concomitant psychiatric therapies (antidepressants, antipsychotics of the first and second generation and mood stabilizers);
  • absence of contraindications for MRI scanning;
  • patients who have signed informed consent.

Exclusion Criteria:

  • age below 18 years or above 40 years;
  • diagnosis different from PPD based on SCID-5;
  • absence of metabolic syndrome;
  • low depression according to the 17-item HAM-D (score less than 14);
  • presence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • presence of concomitant drug therapies (antidepressants, first- and second-generation antipsychotics and mood stabilizers);
  • presence of contraindications for MRI scanning;
  • presence of contraindications for citalopram;
  • patients who have not signed informed consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_ONLY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Women with Post-Partum Depression

15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment.

Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Total White Matter (WM) Volume at Week 12
Tidsramme: Baseline and week 12

Total white matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total WM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

Baseline and week 12
Change From Baseline in Total Gray Matter (GM) Volume at Week 12
Tidsramme: Baseline and week 12

Total gray matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total GM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

Baseline and week 12
Change From Baseline in Total Brain Volume at Week 12
Tidsramme: Baseline and week 12

Total brain volume, expressed in cubic millimeters (mm³), will be calculated as the sum of total gray matter and total white matter volumes obtained from SPM12 segmentation of 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner. A single value per participant will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

Baseline and week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12
Tidsramme: Baseline and week 12

Depressive symptom severity will be assessed with the clinician-administered 21-item Hamilton Depression Rating Scale (HAM-D). Higher scores indicate more severe depression. The change from baseline (week 12 minus baseline) in total score will be reported.

Baseline and week 12
Percentage of Participants Responding to Treatment at Week 12
Tidsramme: Baseline and week 12

Response is defined as a reduction of at least 30% in the 21-item Hamilton Depression Rating Scale (HAM-D) total score at week 12 compared with baseline. Higher HAM-D scores indicate more severe depression. The percentage of participants meeting the response criterion will be reported.

Baseline and week 12

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Adverse Events Related to Citalopram
Tidsramme: From baseline through week 12

Number of participants experiencing at least one serious or non-serious adverse event judged by the medical staff to be related to citalopram, from treatment start through week 12.

From baseline through week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. august 2023

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. juli 2027

Datoer for studieregistrering

Først innsendt

13. april 2023

Først innsendt som oppfylte QC-kriteriene

8. november 2023

Først lagt ut (Faktiske)

14. november 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere